scholarly journals Clinical Drug–Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access

2017 ◽  
Vol 106 (9) ◽  
pp. 2214-2218 ◽  
Author(s):  
Dinko Rekić ◽  
Kellie S. Reynolds ◽  
Ping Zhao ◽  
Lei Zhang ◽  
Kenta Yoshida ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Drug Use ◽  
Drug Access ◽  
Drug Drug Interaction ◽  
Clinical Drug

scholarly journals No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug–Drug Interaction Study

2019 ◽  
Vol 12 (5) ◽  
pp. 513-518 ◽  
Author(s):  
Naoyuki Otani ◽  
Hirokazu Wakuda ◽  
Hiromitsu Imai ◽  
Masae Kuranari ◽  
Yasuyuki Ishii ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Healthy Subjects ◽  
Interaction Study ◽  
Drug Interaction Study ◽  
Drug Drug Interaction ◽  
Clinical Drug

Framework for the Design of Cannabis-Mediated Phase I Drug-Drug Interaction Studies

2021 ◽  
Vol 16 ◽  
Author(s):  
Diana L. Shuster ◽  
Gina Pastino ◽  
Dirk Cerneus
Keyword(s):  
Drug Interaction ◽  
Drug Development ◽  
The United States ◽  
The Body ◽  
Cannabis User ◽  
Special Population ◽  
Care Providers ◽  
Clinical Drug Development ◽  
Drug Drug Interaction ◽  
Clinical Drug

: Cannabis has become legal in much of the United States similarly to many other countries, for either recreational or medical use. The use of cannabis products is rapidly increasing while the body of knowledge of its myriad of effects still lags. In vitro and clinical data show that cannabis’ main constituents, delta-9-tetrahydrocannabinol and cannabidiol, can affect the pharmacokinetics (PK), safety and pharmacodynamics (PD) of other drugs. Within the context of clinical drug development, the widespread and frequent use of cannabis products has essentially created another special population; that is, the cannabis user. We propose that all clinical drug development programs include a Phase 1 study to assess the drug-drug interaction potential of cannabis as a precipitant on the PK, safety and if applicable, the PD of all new molecular entities (NMEs) in a combination of healthy adult subjects as well as frequent and infrequent cannabis users. This data should be required to inform drug labeling and aid health care providers in treating any patient, as cannabis has quickly become another common concomitant medication and cannabis users, a new special population.

scholarly journals ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision

2018 ◽  
Vol 104 (5) ◽  
pp. 781-784 ◽  
Author(s):  
Maciej J. Zamek-Gliszczynski ◽  
Xiaoyan Chu ◽  
Jack A. Cook ◽  
Joseph M. Custodio ◽  
Aleksandra Galetin ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Study Design ◽  
Dose Adjustment ◽  
Efficacy And Safety ◽  
Interaction Study ◽  
Drug Interaction Study ◽  
Drug Drug Interaction ◽  
Clinical Drug

A Clinical Drug‐Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin

2019 ◽  
Vol 106 (6) ◽  
pp. 1398-1407 ◽  
Author(s):  
Christina Trueck ◽  
Chih‐hsuan Hsin ◽  
Oliver Scherf‐Clavel ◽  
Elke Schaeffeler ◽  
Rebekka Lenssen ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Drug Transporter ◽  
Interaction Study ◽  
Drug Interaction Study ◽  
Drug Drug Interaction ◽  
Novel Drug ◽  
Clinical Drug

An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction

2008 ◽  
Vol 36 (7) ◽  
pp. 1198-1201 ◽  
Author(s):  
Melinda J. Reese ◽  
Robert M. Wurm ◽  
Keith T. Muir ◽  
Grant T. Generaux ◽  
Lisa St. John-Williams ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Mechanistic Study ◽  
Drug Drug Interaction ◽  
Clinical Drug
Sign in / Sign up

Export Citation Format

Share Document